Cerebrospinal fluid A beta 1-40 peptides increase in Alzheimer's disease and are highly correlated with phospho-tau in control individuals
By
Sylvain Lehmann,
Julien Dumurgier,
Xavier Ayrignac,
Cecilia Marelli,
Daniel Alcolea,
Juan Fortea-Ormaechea,
Eric Thouvenot,
Constance Delaby,
Christophe Hirtz,
Jerome Vialaret,
Nelly Ginestet,
Elodie Bouaziz-Amar,
Jean-Louis Laplanche,
Pierre Labauge,
Claire Paquet,
Alberto Lleo,
Audrey Gabelle,
ADNI for the Alzheimer's Disease Neuroimaging Initiative
Posted 02 Jun 2020
medRxiv DOI: 10.1101/2020.06.02.20119578
Background: Amyloid pathology, which is one of the characteristics of Alzheimer's disease (AD), results from altered metabolism of the beta-amyloid peptide (A{beta}) in terms of synthesis, clearance or aggregation. A decrease in cerebrospinal fluid (CSF) level A{beta}1-42 is evident in AD, and the CSF ratio A{beta}40 /A{beta}40 has recently been identified as one of the most reliable diagnostic biomarkers of amyloid pathology. Variations in inter-individual levels of A{beta}1-40 in the CSF have been observed in the past, but their origins remain unclear. In addition, the variation of A{beta}40 in the context of AD studied in several studies has yielded conflicting results. Methods: Here, we analyzed the levels of A{beta}1-40 using multicenter data obtained on 2466 samples from six different cohorts in which CSF was collected under standardized protocols, centrifugation and storage conditions. Tau and p-tau(181) concentrations were measured using commercially available in vitro diagnostic immunoassays. Concentrations of CSF A{beta}1-42 and A{beta}1-40 were measured by ELISA, xMAP technology, chemiluminescence immunoassay (CLIA) and mass spectrometry. Statistical analyses were calculated for parametric and non-parametric comparisons, linear regression, correlation and odds ratios. The statistical tests were adjusted for the effects of covariates (age, in particular). Results: Regardless of the analysis method used and the cohorts, a slight but significant age-independent increase in the levels of A{beta}40 in CSF was observed in AD. We also found a strong positive correlation between the levels of A{beta}40 and p-tau(181) in CSF, particularly in control patients. Conclusions: These results indicate that an increase in the baseline level of amyloid peptides, which are associated with an increase in p-tau(181), may be a biological characteristic of AD. This confirms the potential therapeutic value of lowering the baseline levels of A{beta}40 which, being elevated, can be considered a risk factor for the disease.
Download data
- Downloaded 242 times
- Download rankings, all-time:
- Site-wide: 92,435
- In neurology: 241
- Year to date:
- Site-wide: 50,128
- Since beginning of last month:
- Site-wide: 50,128
Altmetric data
Downloads over time
Distribution of downloads per paper, site-wide
PanLingua
News
- 27 Nov 2020: The website and API now include results pulled from medRxiv as well as bioRxiv.
- 18 Dec 2019: We're pleased to announce PanLingua, a new tool that enables you to search for machine-translated bioRxiv preprints using more than 100 different languages.
- 21 May 2019: PLOS Biology has published a community page about Rxivist.org and its design.
- 10 May 2019: The paper analyzing the Rxivist dataset has been published at eLife.
- 1 Mar 2019: We now have summary statistics about bioRxiv downloads and submissions.
- 8 Feb 2019: Data from Altmetric is now available on the Rxivist details page for every preprint. Look for the "donut" under the download metrics.
- 30 Jan 2019: preLights has featured the Rxivist preprint and written about our findings.
- 22 Jan 2019: Nature just published an article about Rxivist and our data.
- 13 Jan 2019: The Rxivist preprint is live!